Evidence map›Paper›PMID 36558900›Full record

ArticlePharmaceuticals (Basel, Switzerland)2022

Antibody-Based In Vivo Imaging of Central Nervous System Targets-Evaluation of a Pretargeting Approach Utilizing a TCO-Conjugated Brain Shuttle Antibody and Radiolabeled Tetrazines.

Christoph Bredack, Martin R Edelmann, Edilio Borroni, Luca C Gobbi, Michael Honer

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Novel Imaging Probes: From Design to Applications.Pharmaceuticals (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Christoph BredackRoche Pharma Research and Early Development, Roche Innovation Center Basel, Neuroscience and Rare Diseases, Biomarkers and Translational Technologies, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland.ORCID 0000-0002-1453-1852
Martin R EdelmannRoche Pharma Research and Early Development, Roche Innovation Center Basel, Therapeutic Modalities, Small Molecule Research, Isotope Synthesis, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland.ORCID 0000-0002-6116-1516
Edilio BorroniRoche Pharma Research and Early Development, Roche Innovation Center Basel, Neuroscience and Rare Diseases, Biomarkers and Translational Technologies, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland.
Luca C GobbiRoche Pharma Research and Early Development, Roche Innovation Center Basel, Therapeutic Modalities, Small Molecule Research, Medicinal Chemistry, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland.ORCID 0000-0002-0563-2491
Michael HonerRoche Pharma Research and Early Development, Roche Innovation Center Basel, Neuroscience and Rare Diseases, Biomarkers and Translational Technologies, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland.
Roche (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bioorthogonal pretargeted imaging using the inverse-electron-demand Diels-Alder (IEDDA) reaction between a tetrazine (Tz) and a

Indexed as

antibodyclick chemistryCNSPETpretargetingtetrazinetrans-cyclooctenetritium

Identifiers

PMID36558900
PMCPMC9787164
OpenAlexW4309839608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.